Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 13, 2014 08:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference

CAMBRIDGE, Mass., Nov. 13, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases,...
November 07, 2014 07:05 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Reports Third Quarter Financial Results and Announces Expansion of Rare Disease Development Portfolio

-- Enrollment achieved in first two dose cohorts of Phase 1/2 Waldenstrom's trial -- Myositis program advanced with specification of Phase 2 clinical trial plan in dermatomyositis -- Rare disease...
November 07, 2014 07:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals and Parent Project Muscular Dystrophy Announce Collaboration to Advance New Treatment Approach for Duchenne Muscular Dystrophy

Toll-like receptor antagonism designed to treat muscle inflammation central to disease progression New approach offers potential to treat broad population of patients regardless of their...
November 06, 2014 09:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Announces Upcoming Presentations of Data From Oncology Programs at Key Scientific Meetings

CAMBRIDGE, Mass., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today...
October 29, 2014 16:30 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals to Announce Third Quarter 2014 Financial Results and Corporate Update on November 7, 2014

CAMBRIDGE, Mass., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with rare...
October 14, 2014 08:00 ET | Source: Aceragen, Inc.

Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of Proprietary TLR Antagonist Candidate IMO-9200

- IND application for Phase 1 clinical trial of IMO-9200 in healthy volunteers accepted by FDA; patient dosing on track to begin in fourth quarter - New IMO-9200 data presented at 10th Annual...